newsfilter
← Latest News
GlobeNewswire·

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

  • RenovoRx, Inc. (NASDAQ: RNXT) announced that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 has been accepted.
  • The company will present findings from a pharmacokinetic & pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial led by Dr. Paula Novelli of the University of Pittsburgh Medical Center.
  • The sub-study compares systemic drug levels of intra-arterial gemcitabine delivered via the RenovoCath device against standard intravenous chemotherapy for locally advanced pancreatic cancer.
  • Dr. Ramtin Agah, Chief Medical Officer, stated the data supports a decreased clinical side effect profile due to lower systemic drug levels with the TAMP™ therapy platform compared to systemic intravenous therapy.
  • The ASCO GI presentation is scheduled for January 9, 2026, at Moscone West in San Francisco, CA, with sessions from 11:30 AM-1:00 PM PT & 5:00-6:00 PM PT.
  • RenovoCath is an FDA-cleared device intended for isolating blood flow & delivering fluids to peripheral vascular sites, including temporary vessel occlusion for chemotherapeutic drug infusion.
  • RenovoRx is in early commercialization stages for RenovoCath, having generated approximately $900,000 in revenue from the device during the first nine months of 2025.
  • The investigational drug-device combination intra-arterial gemcitabine (IAG) is currently under FDA review via a U.S. investigational new drug application & holds Orphan Drug Designation for pancreatic & bile duct cancers.
  • The combination product candidate IAG is not yet approved for commercial sale.
  • The press release includes standard forward-looking statements regarding clinical trial outcomes, commercialization potential, & regulatory milestones subject to various risks & uncertainties.